The First Effect of COVID-19 Pandemic on Starting Biological Disease Modifying Anti-Rheumatic Drugs: Outcomes from the TReasure Real-Life Database

Objective: The coronavirus disease 2019 pandemic has been resulting in increased hospital occupancy rates. Rheumatic patients cannot still reach to hospitals, or they hesitate about going to a hospital even they are able to reach. We aimed to show the effect of the first wave of coronavirus disease 2019 pandemic on the treatment of biological disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis or spondyloarthritis. Methods: Patients were divided into three groups as follows: pre-pandemic (Pre-p: starting on biological disease-modifying anti-rheumatic drug therapy for the first time within 6 months before March 11, 2020); post-pandemic A (Post-p A: starting on biological disease-modifying anti-rheumatic drug therapy for the first time within the first 6 months after March 11, 2020); post-pandemic B (Post-p B: starting on biological disease-modifying anti-rheumatic drug therapy for the first time within the second 6 months). Results: The number of rheumatoid arthritis patients in the Post-p A and B groups decreased by 51% and 48%, respectively, as compared to the Pre-p group similar rates of reduction were also determined in the number of spondyloarthritis patients. The rates of tofacitinib and abatacept use increased in rheumatoid arthritis patients in Post-p period. Conclusion: The number of rheumatoid arthritis and spondyloarthritis patients starting on biological disease-modifying anti-rheumatic drugs for the first time decreased during the first year of the coronavirus disease 2019 pandemic

Smoking May Be Related to Sacroiliitis in Enteropathic Arthritis Patients: Treasure Real-Life Preliminary Data

Annual European Congress of Rheumatology (EULAR) -- JUN 12-15, 2019 -- Madrid, SPAIN[No Abstract Available]European League Against Rheumatis

UVEITIS RELATED FACTORS IN PATIENTS WITH SPONDYLOARTHRITIS

Annual European Congress of Rheumatology (EULAR) -- JUN 12-15, 2019 -- Madrid, SPAIN[No Abstract Available]European League Against Rheumatis

Analysis of the common genetic component of large-vessel vasculitides through a meta- Immunochip strategy

Giant cell arteritis (GCA) and Takayasu's arteritis (TAK) are major forms of large-vessel vasculitis (LVV) that share clinical features. To evaluate their genetic similarities, we analysed Immunochip genotyping data from 1,434 LVV patients and 3,814 unaffected controls. Genetic pleiotropy was also estimated. The HLA region harboured the main disease-specific associations. GCA was mostly associated with class II genes (HLA-DRB1/HLA-DQA1) whereas TAK was mostly associated with class I genes (HLA-B/MICA). Both the statistical significance and effect size of the HLA signals were considerably reduced in the cross-disease meta-analysis in comparison with the analysis of GCA and TAK separately. Consequently, no significant genetic correlation between these two diseases was observed when HLA variants were tested. Outside the HLA region, only one polymorphism located nearby the IL12B gene surpassed the study-wide significance threshold in the meta-analysis of the discovery datasets (rs755374, P?=?7.54E-07; ORGCA?=?1.19, ORTAK?=?1.50). This marker was confirmed as novel GCA risk factor using four additional cohorts (PGCA?=?5.52E-04, ORGCA?=?1.16). Taken together, our results provide evidence of strong genetic differences between GCA and TAK in the HLA. Outside this region, common susceptibility factors were suggested, especially within the IL12B locus

Comparison Of Biopsychosocial Status Of Patients With Ankylosing Spondylitis With And Without Anti-Tnf Treatment

Wo

Romatolojide gerçek yaşam verileri

Gerçek yaşam verileri hasta anketleri, klinik araştırmalar ve gözlemsel kohort çalışmaları yoluyla, günlük yaşamda heterojen bir hasta popülasyonundan elde edilen verilerdir. Gerçek yaşam verileri araştırmacılar, klinisyenler, medikal endüstrisi ve devletler tarafından giderek daha fazla talep edilmektedir. Bunun en büyük nedeni ise klinik bulguları gerçek hayatta doğrulamanın yani bilimsel gerçekleri test etmenin en iyi yolu olmasıdır. Bu nedenle, gerçek yaşam verileri kayıt altına alınmalı ve analiz edilmelidir. Bu yazıda, gerçek yaşam verilerinin özelliklerini, avantajlarını ve dezavantajlarını tüm dünyadan örneklerle açıklamayı amaçladık.Real-world data is derived from many sources associated with outcomes in a heterogeneous patient population in real-world settings, such as patient surveys, clinical trials, and observational cohort studies. Realworld data is increasingly being demanded by researchers, clinicians, the medical industries, and governments. To validate the clinical findings in real life is the best way to test scientific facts. For this reason, real-world data should be collected and analyzed well. In this article, we aimed to clarify the features, advantages, and disadvantages of real world data with examples from all over the world

A new biopsychosocial questionnaire (BETY-BQ) for patients with ankylosing spondylitis

Introduction: Scales for biopsychosocial evaluation of patients are limited. This study assessed the validity, reliability, and responsiveness of a Cognitive Exercise Therapy Approach-Biopsychosocial Questionnaire (Bilişsel Egzersiz Terapi Yaklaşımı-Biopsychosocial Questionnaire; BETY-BQ) in patients with ankylosing spondylitis (AS). Methods: Health Assessment Questionnaire for Spondyloarthropathies (HAQ-S), Ankylosing Spondylitis Quality of Life Questionnaire (ASQoL), Hospital Anxiety and Depression Scale (HADS), Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), and Bath Ankylosing Spondylitis Functional Index (BASFI), were selected to investigate the validity of the BETY-BQ. Spearman's correlation coefficient was used as the data were not normally distributed. For scale reliability, the test-retest method was performed, Intraclass Correlation Coefficient (ICC) was calculated and Cronbach's alpha (α) coefficient was checked for internal consistency. The same scales were applied to patients under medical treatment at 3-month intervals for the determination of responsiveness. Results: A total of 157 individuals took part, including 106 (67.5%) male participants and 51 (32.5%) female participants, with a mean age of 43.86±11.60 years. The correlations of BETY-BQ with the HAQ-S, ASQoL, HADS, BASDAI, and BASFI were very high to moderate (r = 0.819 to r = 0.583, p<0.001). The test-retest method was used for reliability, and the correlation between the responses was very high (r = 0.846, p<0.001). The ICC (r = 0.944, p<0.001) and the Cronbach's α value (0.936) were checked and were found to be excellent. In the correlation analysis of time-dependent changes, a weak to high correlation was found between BETY-BQ and the other scales (r = 0.672 to r = 0.285, p<0.001). As a result of the confirmatory factor analysis, it was determined that all goodness-of-fit indices of BETY-BQ except GFI were suitable and the construct validity of the scale was ensured. Conclusion: A valid, reliable and responsive biopsychosocial questionnaire BETY- BQ was added to the literature. This scale is easy-to-understand and practical, and can be used both in the clinic and in research for the biopsychosocial assessment of individuals